INCB 54828

Drug Profile

INCB 54828

Alternative Names: INCB 054828; INCB54828

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma; Lymphoid leukaemia; Myeloid leukaemia; Myeloproliferative disorders; Urogenital cancer
  • Phase I/II Multiple myeloma; Solid tumours

Most Recent Events

  • 22 Mar 2017 Incyte corporation has patent protection for INCB 054828 in European Union and Japan (Incyte corporation form 10-k, March 2017)
  • 22 Mar 2017 Incyte corporation has patents pending for INCB 054828 in USA (Incyte corporation Form 10-K, March 2017)
  • 01 Mar 2017 Phase-II clinical trials in Myeloproliferative disorders (PO) before March 2017 (Incyte corporation form 10-k, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top